Veristat Launches AI-Powered Biostatistics Platform to Accelerate Clinical Trial Data Analysis
核心洞察
Veristat (搜索) has launched InStat, the clinical research industry's first zero-code, fully automated biostatistics solution that reduces clinical trial data readout time from 4-6 weeks to 5 days or less.
The platform delivers submission-ready tables, listings, and figures backed by validated statistical engines and expert biostatistician review, with Clene Nanomedicine as its first customer for NfL (搜索) biomarker analyses.
Traditional delays in biostatistical analysis can cost sponsors $500,000 or more per day in unrealized sales, making this acceleration potentially significant for drug development timelines.
Veristat (搜索), a global clinical research organization specializing in complex studies, has announced the launch of InStat by Veristat, positioning it as the clinical research industry's first zero-code, fully automated biostatistics solution. The platform promises to dramatically reduce the time required for clinical trial data analysis from the traditional 4-6 weeks to five days or less, while maintaining regulatory compliance and data quality standards.
Revolutionary Speed in Clinical Data Processing
The InStat platform addresses a critical bottleneck in drug development where sponsors traditionally wait weeks for biostatisticians to manually analyze volumes of study data after database lock. According to Veristat (搜索), such delays can cost sponsors $500,000 or more per day in potential, unrealized sales while patients remain burdened by their disease.
"InStat is a modern solution built off a foundation of two decades of proven biostatistical analysis," said Kyle McBride, Veristat (搜索) Vice President, AI & Innovation. "We intentionally put AI where it adds speed, not where it adds risk: assisting biostatisticians in translating analytical intent into precise specifications. Once that's right, everything downstream is trustworthy."
First Customer Success with Clene Nanomedicine
Clene Nanomedicine has become the first clinical trial sponsor to utilize InStat for their biostatistical analyses, specifically for NfL (搜索) biomarker analyses supporting their planned 2026 New Drug Application (NDA) for CNM-Au8.
"Following recent FDA interactions, we are advancing our NDA submission for CNM-Au8 with NfL (搜索) biomarker concordance evidence as a core component of the accelerated approval pathway argument under Subpart H," said Michael Hotchkin, Chief Development Officer at Clene Nanomedicine. "Veristat (搜索) produced the supporting NfL biomarker analyses with InStat, delivering tables in days rather than the weeks that similar analyses typically demand, and our biostatistics team verified the outputs through detailed review."
Technical Innovation Without Regulatory Risk
The InStat platform distinguishes itself by using AI agents that convert biostatistician descriptions into precise specifications, which then drive a library of validated statistical engines to perform every analytical step. This approach enables automation speed without the regulatory exposure associated with LLM-generated analysis code.
The platform delivers submission-ready tables, listings, and figures (TLF) with every output backed by validated statistical engines and expert biostatistician review. Additionally, InStat enables transparent, collaborative readout reviews through a secure online portal where sponsors can work directly with Veristat (搜索) in real time to finalize biostatistical readouts.
System Flexibility and Implementation
InStat is designed to be system-agnostic, allowing sponsors to use their preferred electronic data capture systems while maintaining their unique formatting requirements. Veristat (搜索) plans to begin using InStat to deliver biostatistics services starting in June.
The company, which has 30 years of experience and has supported more than 100 regulatory approvals, specializes in rare disease (搜索), neurological disease (搜索), oncology (搜索), and advanced therapies. Veristat (搜索) is hosting a limited-invite event featuring Ken Getz, Executive Director and Research Professor at the Tufts Center for the Study of Drug Development, on May 18, 2026 in Boston to demonstrate the platform's capabilities.